Sugi Predict

Sugi Predict / Targets / ATP6V1H

ATP6V1H

V-type proton ATPase subunit H · Q9UI12 · ATP6V1H on Sugi Atlas →

0 patent compounds predicted against ATP6V1H, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to ATP6V1H by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
The Possible Efficacy and Safety of Lansoprazole Co-administration With Neoadjuvant Chemotherapy in Women With Breast Cancer PHASE3COMPLETED
Applying Proton Pump Inhibitor to Prevent and Treat Acute Fluctuating Hearing Loss in Patients With SLC26A4 Mutation PHASE2/PHASE3UNKNOWN
Copper Histidine Therapy for Menkes Diseases PHASE1/PHASE2COMPLETED
Vacuolar ATPase and Drug Resistance of High Grade Gliomas nanUNKNOWN
Natural History Study of ATP1A3-related Disease nanUNKNOWN
Biomarkers in the Etiology of Idiopathic Intracranial Hypertension nanUNKNOWN
Prescreening Study to Identify Potential Wilson Disease Participants for Gene-Editing Clinical Trial nanACTIVE_NOT_RECRUITING
Impact of Sulphonylureas on Neurodevelopmental Outcomes in KCNJ11-related Intermediate Developmental Delay, Epilepsy and Neonatal Diabetes (iDEND) Syndrome nanRECRUITING
Role for Biochemical Assays and Kayser-Fleischer Rings in Diagnosis of Wilson Disease nanRECRUITING
Establishment of Human Cellular Disease Models for Wilson Disease nanCOMPLETED
Genetic Analysis of Hereditary Disorders of Hearing and Balance nanCOMPLETED
Clinical and Genetic Analysis of Enlarged Vestibular Aqueducts nanCOMPLETED
Phenotypic and Genotypic Studies in Congenital and Early Onset Ataxias nanCOMPLETED
Study of Usher Syndromes, Type 1 and Type 2 nanCOMPLETED
Identification of New Candidate Genes in Patients With Mitochondrial Disease by High Resolution Chromosome Analysis on DNA Chip nanCOMPLETED
Nuclear Myosin VI - a Therapeutic Target in Breast Cancer nanUNKNOWN
Genetic Analysis of Patients With Pseudoxanthoma Elasticum nanCOMPLETED
Longitudinal Assessment of Atypical Tripeptidyl Peptidase 1 Enzyme Deficiency Patients nanACTIVE_NOT_RECRUITING
GDF-15 as a Biomarker for Mitochondrial Disease nanCOMPLETED
Diagnosis of Primary Ciliary Dyskinesia nanCOMPLETED
the Effect of ABCC2 Genetic Polymorphism on Neurotoxicity in Gastrointestinal Cancer Patients Receiving Oxaliplatin nanUNKNOWN
Pharmacogenomics of New Antiretrovirals nanCOMPLETED
Validation of a Prognostic Biomarker Using Brain Diffusion MRI in X-linked Adrenoleukodystrophy nanNOT_YET_RECRUITING
Genetic Testing in Detection of Late-Onset Hearing Loss nanCOMPLETED
Oxalate and Citrate in Humans - Response to Citrate nanRECRUITING
Exome Analysis in Hearing Impaired Patients nanUNKNOWN
Coproporphyrine Isomers and Methotrexate Elimination nanCOMPLETED
The Energetic Origin of Neurodegeneration in MS nanCOMPLETED
DEFINING THE GENETIC DRIVERS OF ADULT-ONSET CHOLESTATIC LIVER DISEASE nanRECRUITING
Tissue Sample Study for Mitochondrial Disorders nanENROLLING_BY_INVITATION

Related proteins — ESM-2 sequence neighbours (a ATP6V1H binder may also engage these)

ProteinNameSimilarity
O46563 — 1.000 O46563 →
Q8BVE3 — 1.000 Q8BVE3 →
Q9TVC1 — 1.000 Q9TVC1 →
Q84ZC0 — 0.998 Q84ZC0 →
Q9LX65 — 0.991 Q9LX65 →
Q9V3J1 — 0.990 Q9V3J1 →
Q9U5N0 — 0.989 Q9U5N0 →
Q9I8E6 — 0.985 Q9I8E6 →
Q9QZE5 — 0.985 Q9QZE5 →
Q9PUE4 — 0.984 Q9PUE4 →
Q6P2K6 — 0.984 Q6P2K6 →
Q9QXK3 — 0.984 Q9QXK3 →
XPO5 Exportin-5 0.984 landscape →
P53620 — 0.983 P53620 →
Q9H892 — 0.983 Q9H892 →
Q68F38 — 0.983 Q68F38 →
COPG1 Coatomer subunit gamma-1 0.982 landscape →
Q66JI9 — 0.982 Q66JI9 →
PPP4R3A Serine/threonine-protein phosphatase 4 regulatory subunit 3A 0.982 landscape →
A2VE70 — 0.982 A2VE70 →
P22892 — 0.982 P22892 →
COPG2 Coatomer subunit gamma-2 0.982 landscape →
Q6INN7 — 0.981 Q6INN7 →
Q8LF36 — 0.981 Q8LF36 →
Q66L58 — 0.981 Q66L58 →
Q0P5A6 — 0.981 Q0P5A6 →
Q16537 — 0.981 Q16537 →
A4FV68 — 0.981 A4FV68 →
Q5RAG3 — 0.981 Q5RAG3 →
Q8N3U4 — 0.981 Q8N3U4 →